The Clinical Value of Computed Tomography -Guided [.sup.125]I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy
Purpose: To further evaluate the efficacy and safety of computed tomography (CT)-guided iodine 125 ([.sup.125]I) brachytherapy to treat locally advanced non-small cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT). Methods: This study obtained written consent from all...
Gespeichert in:
| Veröffentlicht in: | Cancer management and research 2021-07, Vol.13, p.5297 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 5297 |
| container_title | Cancer management and research |
| container_volume | 13 |
| creator | Xiang, Zhanwang Zhong, Zhihui Mu, Luwen Li, Guohong Zhou, Churen Wang, Haofan Huang, Mingsheng |
| description | Purpose: To further evaluate the efficacy and safety of computed tomography (CT)-guided iodine 125 ([.sup.125]I) brachytherapy to treat locally advanced non-small cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT). Methods: This study obtained written consent from all patients and was approved by our institution. From January 2006 to June 2018, 210 NSCLC patients (progression of first-line CCRT) were retrospectively recruited and then divided into two groups. A total of 116 patients were given CT-guided [.sup.125]I brachytherapy and second-line chemotherapy (group A), and 94 were treated with second-line chemotherapy alone (group B). Results: In group A, local response rate (LRR) within 3 years was significantly better (P |
| doi_str_mv | 10.2147/CMAR.S313438 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A672726823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A672726823</galeid><sourcerecordid>A672726823</sourcerecordid><originalsourceid>FETCH-LOGICAL-g673-fef035cd11a3cf67a5216ae5ee497a69ffc083b92d0b8ef400ae3d83f9f23c6a3</originalsourceid><addsrcrecordid>eNptj9tKw0AQhoMoWKt3PsCC14l7yPEyBq2FeKAN3oiU7e5ss5LslhyEPJTv6Ep74YUMzAz_fDM_43nXBAeUhMlt8ZSvgjUjLGTpiTcjJMl8wig9_dOfexd9_4lxnDls5n1XNaCi0UYL3qA33oyArEKFbffjABJVtrW7ju_rCfmLUUsnvQf9uA8IjT6W6K7jop6GGhwyIWU7VFp3qJlQLr-4EQ5_tsZft05DBbhUjmaHit9Rh3I1uPzaOQfoe23NwdqIsevADGjFpbaihtYeHS69M8WbHq6Ode5VD_dV8eiXL4tlkZf-Lk6Yr0BhFglJCGdCxQmPKIk5RABhlvA4U0rglG0zKvE2BRVizIHJlKlMUSZizubezeHsjjew0UbZwf3Z6l5s8jihCY1TyhwV_EO5kNBqYQ0o7fQ_Cz_X84GQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Clinical Value of Computed Tomography -Guided [.sup.125]I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy</title><source>Taylor & Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Dove Press Free</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Xiang, Zhanwang ; Zhong, Zhihui ; Mu, Luwen ; Li, Guohong ; Zhou, Churen ; Wang, Haofan ; Huang, Mingsheng</creator><creatorcontrib>Xiang, Zhanwang ; Zhong, Zhihui ; Mu, Luwen ; Li, Guohong ; Zhou, Churen ; Wang, Haofan ; Huang, Mingsheng</creatorcontrib><description>Purpose: To further evaluate the efficacy and safety of computed tomography (CT)-guided iodine 125 ([.sup.125]I) brachytherapy to treat locally advanced non-small cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT). Methods: This study obtained written consent from all patients and was approved by our institution. From January 2006 to June 2018, 210 NSCLC patients (progression of first-line CCRT) were retrospectively recruited and then divided into two groups. A total of 116 patients were given CT-guided [.sup.125]I brachytherapy and second-line chemotherapy (group A), and 94 were treated with second-line chemotherapy alone (group B). Results: In group A, local response rate (LRR) within 3 years was significantly better (P<0.05). Mean survival time [progression-free survival time (PFST) and overall survival (OS)] was 15.1[+ or -]1.4 months and 21.2[+ or -]1.6 months in group A compared with 10.0[+ or -]1.4 months and 16.2[+ or -]1.7 months in group B (PFST: P<0.01, HR=1.472, 95% CI 1.097-1.975; OS: P = 0.036, HR=1.342, 95% CI 1.005-1.791). Tumor size and No. of first cycle chemotherapy were independent factors that affected survival, [less than or equal to]3cm largest tumor diameter and more than 4 first cycles of chemotherapy showed longer PFST and OS (P<0.05). Tumor-related clinical symptoms were relieved in group A (P<0.01). No serious complications occurred in the two groups. Conclusion: [.sup.125]I brachytherapy is effective and safe in locally advanced NSCLC after progression of CCRT. Keywords: [.sup.125]I, brachytherapy, NSCLC, concurrent radiochemotherapy, efficacy, safety</description><identifier>ISSN: 1179-1322</identifier><identifier>EISSN: 1179-1322</identifier><identifier>DOI: 10.2147/CMAR.S313438</identifier><language>eng</language><publisher>Dove Medical Press Limited</publisher><subject>Cancer ; Chemotherapy ; CT imaging ; Development and progression ; Diagnostic imaging ; Lung cancer, Non-small cell ; Lung cancer, Small cell ; Medical research ; Medicine, Experimental ; Pemetrexed ; Radioisotope brachytherapy</subject><ispartof>Cancer management and research, 2021-07, Vol.13, p.5297</ispartof><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27903,27904</link.rule.ids></links><search><creatorcontrib>Xiang, Zhanwang</creatorcontrib><creatorcontrib>Zhong, Zhihui</creatorcontrib><creatorcontrib>Mu, Luwen</creatorcontrib><creatorcontrib>Li, Guohong</creatorcontrib><creatorcontrib>Zhou, Churen</creatorcontrib><creatorcontrib>Wang, Haofan</creatorcontrib><creatorcontrib>Huang, Mingsheng</creatorcontrib><title>The Clinical Value of Computed Tomography -Guided [.sup.125]I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy</title><title>Cancer management and research</title><description>Purpose: To further evaluate the efficacy and safety of computed tomography (CT)-guided iodine 125 ([.sup.125]I) brachytherapy to treat locally advanced non-small cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT). Methods: This study obtained written consent from all patients and was approved by our institution. From January 2006 to June 2018, 210 NSCLC patients (progression of first-line CCRT) were retrospectively recruited and then divided into two groups. A total of 116 patients were given CT-guided [.sup.125]I brachytherapy and second-line chemotherapy (group A), and 94 were treated with second-line chemotherapy alone (group B). Results: In group A, local response rate (LRR) within 3 years was significantly better (P<0.05). Mean survival time [progression-free survival time (PFST) and overall survival (OS)] was 15.1[+ or -]1.4 months and 21.2[+ or -]1.6 months in group A compared with 10.0[+ or -]1.4 months and 16.2[+ or -]1.7 months in group B (PFST: P<0.01, HR=1.472, 95% CI 1.097-1.975; OS: P = 0.036, HR=1.342, 95% CI 1.005-1.791). Tumor size and No. of first cycle chemotherapy were independent factors that affected survival, [less than or equal to]3cm largest tumor diameter and more than 4 first cycles of chemotherapy showed longer PFST and OS (P<0.05). Tumor-related clinical symptoms were relieved in group A (P<0.01). No serious complications occurred in the two groups. Conclusion: [.sup.125]I brachytherapy is effective and safe in locally advanced NSCLC after progression of CCRT. Keywords: [.sup.125]I, brachytherapy, NSCLC, concurrent radiochemotherapy, efficacy, safety</description><subject>Cancer</subject><subject>Chemotherapy</subject><subject>CT imaging</subject><subject>Development and progression</subject><subject>Diagnostic imaging</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung cancer, Small cell</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Pemetrexed</subject><subject>Radioisotope brachytherapy</subject><issn>1179-1322</issn><issn>1179-1322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptj9tKw0AQhoMoWKt3PsCC14l7yPEyBq2FeKAN3oiU7e5ss5LslhyEPJTv6Ep74YUMzAz_fDM_43nXBAeUhMlt8ZSvgjUjLGTpiTcjJMl8wig9_dOfexd9_4lxnDls5n1XNaCi0UYL3qA33oyArEKFbffjABJVtrW7ju_rCfmLUUsnvQf9uA8IjT6W6K7jop6GGhwyIWU7VFp3qJlQLr-4EQ5_tsZft05DBbhUjmaHit9Rh3I1uPzaOQfoe23NwdqIsevADGjFpbaihtYeHS69M8WbHq6Ode5VD_dV8eiXL4tlkZf-Lk6Yr0BhFglJCGdCxQmPKIk5RABhlvA4U0rglG0zKvE2BRVizIHJlKlMUSZizubezeHsjjew0UbZwf3Z6l5s8jihCY1TyhwV_EO5kNBqYQ0o7fQ_Cz_X84GQ</recordid><startdate>20210731</startdate><enddate>20210731</enddate><creator>Xiang, Zhanwang</creator><creator>Zhong, Zhihui</creator><creator>Mu, Luwen</creator><creator>Li, Guohong</creator><creator>Zhou, Churen</creator><creator>Wang, Haofan</creator><creator>Huang, Mingsheng</creator><general>Dove Medical Press Limited</general><scope/></search><sort><creationdate>20210731</creationdate><title>The Clinical Value of Computed Tomography -Guided [.sup.125]I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy</title><author>Xiang, Zhanwang ; Zhong, Zhihui ; Mu, Luwen ; Li, Guohong ; Zhou, Churen ; Wang, Haofan ; Huang, Mingsheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g673-fef035cd11a3cf67a5216ae5ee497a69ffc083b92d0b8ef400ae3d83f9f23c6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer</topic><topic>Chemotherapy</topic><topic>CT imaging</topic><topic>Development and progression</topic><topic>Diagnostic imaging</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung cancer, Small cell</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Pemetrexed</topic><topic>Radioisotope brachytherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xiang, Zhanwang</creatorcontrib><creatorcontrib>Zhong, Zhihui</creatorcontrib><creatorcontrib>Mu, Luwen</creatorcontrib><creatorcontrib>Li, Guohong</creatorcontrib><creatorcontrib>Zhou, Churen</creatorcontrib><creatorcontrib>Wang, Haofan</creatorcontrib><creatorcontrib>Huang, Mingsheng</creatorcontrib><jtitle>Cancer management and research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xiang, Zhanwang</au><au>Zhong, Zhihui</au><au>Mu, Luwen</au><au>Li, Guohong</au><au>Zhou, Churen</au><au>Wang, Haofan</au><au>Huang, Mingsheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Clinical Value of Computed Tomography -Guided [.sup.125]I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy</atitle><jtitle>Cancer management and research</jtitle><date>2021-07-31</date><risdate>2021</risdate><volume>13</volume><spage>5297</spage><pages>5297-</pages><issn>1179-1322</issn><eissn>1179-1322</eissn><abstract>Purpose: To further evaluate the efficacy and safety of computed tomography (CT)-guided iodine 125 ([.sup.125]I) brachytherapy to treat locally advanced non-small cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT). Methods: This study obtained written consent from all patients and was approved by our institution. From January 2006 to June 2018, 210 NSCLC patients (progression of first-line CCRT) were retrospectively recruited and then divided into two groups. A total of 116 patients were given CT-guided [.sup.125]I brachytherapy and second-line chemotherapy (group A), and 94 were treated with second-line chemotherapy alone (group B). Results: In group A, local response rate (LRR) within 3 years was significantly better (P<0.05). Mean survival time [progression-free survival time (PFST) and overall survival (OS)] was 15.1[+ or -]1.4 months and 21.2[+ or -]1.6 months in group A compared with 10.0[+ or -]1.4 months and 16.2[+ or -]1.7 months in group B (PFST: P<0.01, HR=1.472, 95% CI 1.097-1.975; OS: P = 0.036, HR=1.342, 95% CI 1.005-1.791). Tumor size and No. of first cycle chemotherapy were independent factors that affected survival, [less than or equal to]3cm largest tumor diameter and more than 4 first cycles of chemotherapy showed longer PFST and OS (P<0.05). Tumor-related clinical symptoms were relieved in group A (P<0.01). No serious complications occurred in the two groups. Conclusion: [.sup.125]I brachytherapy is effective and safe in locally advanced NSCLC after progression of CCRT. Keywords: [.sup.125]I, brachytherapy, NSCLC, concurrent radiochemotherapy, efficacy, safety</abstract><pub>Dove Medical Press Limited</pub><doi>10.2147/CMAR.S313438</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1179-1322 |
| ispartof | Cancer management and research, 2021-07, Vol.13, p.5297 |
| issn | 1179-1322 1179-1322 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A672726823 |
| source | Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; Dove Press Free; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Cancer Chemotherapy CT imaging Development and progression Diagnostic imaging Lung cancer, Non-small cell Lung cancer, Small cell Medical research Medicine, Experimental Pemetrexed Radioisotope brachytherapy |
| title | The Clinical Value of Computed Tomography -Guided [.sup.125]I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T13%3A19%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Clinical%20Value%20of%20Computed%20Tomography%20-Guided%20%5B.sup.125%5DI%20Brachytherapy%20for%20Locally%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20After%20Progression%20of%20Concurrent%20Radiochemotherapy&rft.jtitle=Cancer%20management%20and%20research&rft.au=Xiang,%20Zhanwang&rft.date=2021-07-31&rft.volume=13&rft.spage=5297&rft.pages=5297-&rft.issn=1179-1322&rft.eissn=1179-1322&rft_id=info:doi/10.2147/CMAR.S313438&rft_dat=%3Cgale%3EA672726823%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A672726823&rfr_iscdi=true |